Texas THC ban proposal hits a snag in Austin

Texas lawmakers are grappling with a proposed ban on consumable THC products, specifically targeting chemical variants like delta-8, while maintaining legality for non-intoxicating hemp-derived THC (below 0.3%) and CBD/CBG. Despite aggressive efforts by Lt. Gov. Dan Patrick and two special legislative sessions, key bills (SB6, HB6) are stalled in the House committee with no hearings scheduled. This legislative stalemate creates significant regulatory uncertainty for the state's hemp-derived product market as the current session nears its September 14 deadline.

Analysis

The regulatory landscape for Texas's consumable hemp-derived products market is defined by significant legislative uncertainty, creating a high-risk environment for operators. A proposal, Senate Bill 6, which seeks to outlaw intoxicating chemical variants like delta-8 THC, has stalled in a House committee despite a strong political push from Lt. Gov. Dan Patrick during two special legislative sessions. With the committee chair having not scheduled a hearing and a key staffer describing the bill's future as "up in the air," the immediate threat of a ban is diminishing as the September 14 session deadline approaches. This legislative gridlock provides a temporary, albeit precarious, reprieve for businesses in the state's delta-8 market. The proposed legislation's distinction, which would permit non-intoxicating cannabinoids like CBD, CBG, and products with under 0.3% THC, highlights a potential bifurcation of the market, but the overall sector remains highly vulnerable to future political and regulatory shifts.

Key Decisions for Investors

• Investors with exposure to companies in the Texas hemp-derived products market must recognize the current legislative stalemate is a temporary reprieve, not a permanent resolution, and should price in a high regulatory risk premium for any assets in this sector.
• Closely monitor legislative developments up to the September 14 deadline and in subsequent sessions, as the failure to pass a ban now does not eliminate the substantial long-term risk of prohibition.
• It may be prudent to differentiate between companies reliant on intoxicating products like delta-8, which face existential risk, and those focused on CBD, CBG, and low-THC products that appear insulated from the current legislative threat.